Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

- PMLiVE

Alzheimer’s Research UK welcomes ambitions for dementia set out in first women’s health strategy

The ten-year strategy follows the charity’s calls for action to tackle dementia’s disproportionate impact on women

- PMLiVE

Bristol Myers Squibb launches initiative to ensure disability diversity in clinical trials

Current common clinical trial practices exclude up to a quarter of the US population based on disability status

- PMLiVE

Sandoz’s biosimilar medicine application accepted by FDA

If approved, the higher concentration formulation could decrease the number of injections required for patients currently receiving a lower dose of Hyrimoz

COS and Genesis Research

Genesis Research and Clinical Outcomes Solutions announce innovative partnership

International Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) organization Genesis Research is delighted to announce an exciting new partnership with Clinical Outcomes Assessment (COA) specialist Clinical Outcomes...

Genesis Research Group

- PMLiVE

Almirall launches call on AlmirallShare to find innovative therapies for skin diseases

Since its launch, the R&D platform has received over 560 proposals from over 50 countries

- PMLiVE

Biopharma industry launches Berlin Declaration to ensure equal access during future pandemics

The Declaration outlines a framework that could help to ensure that lower-income countries receive pandemic vaccines and treatments

- PMLiVE

FDA approves Incyte’s Opzelura for vitiligo

It is the first and only FDA-approved product for repigmentation in patients with nonsegmental vitiligo

EcoVadis silver badge

Cuttsy+Cuttsy’s first EcoVadis rating comes back silver!

Louise Jones, Sustainability Officer at Cuttsy+Cuttsy celebrates their new silver sustainability rating

Cuttsy + Cuttsy

- PMLiVE

Nucleus Global are winners of ‘Medical Affairs Agency of the Year’ at Communiqué 2022

Triple success across Inizio at the leading European Healthcare Communications Awards

Nucleus Global

- PMLiVE

AbbVie submits migraine prevention drug to EMA for marketing authorisation

If approved, atogepant would be the first daily oral CGRP receptor antagonist migraine treatment for adults in Europe

- PMLiVE

Roche’s diagnostic test for Alzheimer’s receives FDA Breakthrough Device Designation

Alzheimer's affects more than 55 million people globally and is the most common form of dementia

- PMLiVE

NICE recommends Rhythm Pharmaceuticals’ Imcivree for severe obesity and hyperphagia

The treatment will be funded and available for use within 90 days in the NHS

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links